Flecainide: Nursing Drug Guide, Proarrhythmia & ECG Monitoring

Flecainide is available as flecainide acetate tablets, USP (50 mg, 100 mg, and 150 mg) from multiple manufacturers including Hikma Pharmaceuticals USA Inc. Verify the MAR lists both generic and brand names when present—antiarrhythmic tablets are high-stakes look-alike products in automated dispensing cabinets.

Tablet imprints vary by manufacturer (e.g., Hikma 50 mg “54 024”, 100 mg “54 070”, 150 mg “54 150”). Confirm strength before administration; dose errors between 50 mg and 150 mg tablets carry proarrhythmia risk.

Per flecainide acetate prescribing information, flecainide is reserved for patients in whom benefits outweigh proarrhythmic risks. In patients without structural heart disease, it is indicated for prevention of paroxysmal supraventricular tachycardias (PSVT)—including atrioventricular nodal reentrant tachycardia (AVNRT)—and paroxysmal atrial fibrillation/flutter associated with disabling symptoms.

Flecainide is also indicated for prevention of documented life-threatening ventricular arrhythmias such as sustained ventricular tachycardia. Initiation for sustained VT should occur in the hospital with rhythm monitoring. It is not recommended for less severe ventricular arrhythmias even if symptomatic, after recent myocardial infarction, or for chronic atrial fibrillation (inadequately studied).

↔On a small screen, swipe or scroll sideways to see the full table.

Flecainide is a Class IC membrane-stabilizing antiarrhythmic with local anesthetic activity. It produces dose-related decreases in intracardiac conduction, with the greatest effect on His-Purkinje (H-V) conduction. It slows AV nodal and intra-atrial conduction to a lesser degree and can suppress PVCs and recurrent ventricular tachycardia.

Unlike negative chronotropes used for rate control alone, flecainide directly alters conduction velocity—nurses should expect PR and QRS widening on the ECG rather than isolated heart-rate slowing. It has a negative inotropic effect and may worsen heart failure in susceptible patients.

Steady-state plasma levels may take 3 to 5 days; increase doses no more frequently than every four days. Most proarrhythmic events in sustained VT patients occurred within the first 14 days—hospital initiation and ECG surveillance are essential.

Paroxysmal supraventricular arrhythmias (PSVT / PAF)

Sustained ventricular tachycardia (in hospital)

Renal impairment

Severe renal impairment (creatinine clearance ≤35 mL/min/1.73 m²): initial dose 100 mg once daily or 50 mg twice daily; frequent plasma level monitoring required. Less severe renal disease: start 100 mg every 12 hours with cautious titration.

Amiodarone combination: Reduce usual flecainide dose by 50% and monitor closely; plasma levels may increase two-fold or more.

Therapeutic trough levels: Most successfully treated patients have trough plasma levels 0.2–1 mcg/mL; levels above 0.7–1 mcg/mL are associated with higher rates of cardiac adverse experiences.

Pretreatment checks

• Perform medication reconciliation—screen for amiodarone, digoxin, beta blockers, and other negative inotropes
• Review baseline 12-lead ECG: PR, QRS, QT; obtain rhythm strip per protocol
• Assess history of MI, structural heart disease, heart failure, sick sinus syndrome, and pacemaker dependence
• Check renal function (eGFR/creatinine clearance) for dose selection and monitoring frequency
• Correct preexisting hypokalemia or hyperkalemia before administration

Contraindications

• Pre-existing second- or third-degree AV block
• Right bundle branch block with left hemiblock (bifascicular block) unless pacemaker present
• Cardiogenic shock
• Known hypersensitivity to flecainide
• Recent myocardial infarction (label warning—not recommended)

Warnings (labeling)

• Proarrhythmia: New or worsened VT/VF, increased PVCs, or harder-to-treat supraventricular arrhythmias—often within first 14 days for VT patients
• CAST mortality: Excess death/non-fatal cardiac arrest in post-MI patients with non-life-threatening ventricular arrhythmias
• Conduction effects: PR increase ~25% (up to 118%); ~one-third develop new first-degree AV block; QRS may reach ≥0.12 s
• Heart failure: Negative inotropy—use cautiously with CHF history; initial dose ≤100 mg bid
• Atrial flutter/fibrillation: Risk of 1:1 AV conduction or paradoxical ventricular rate increase; chronic AF not recommended
• Pacemaker patients: Increases pacing thresholds—verify capture before and during therapy

Important interactions

↔On a small screen, swipe or scroll sideways to see the full table.

Route: Oral tablet (50 mg, 100 mg, 150 mg). Absorption is nearly complete; peak levels occur at about three hours (range 1–6 hours). Food and antacids do not affect absorption.

• Administer at ordered interval—typically every 12 hours; some patients may use every 8 hours if not controlled at 12-hour intervals
• Verify tablet strength against MAR; independent double-check high-risk antiarrhythmic doses
• Do not crush or split unless pharmacy confirms and prescriber orders—use correct scored tablet when half-doses required
• When transferring from another antiarrhythmic, allow 2–4 half-lives of the prior drug to elapse before starting flecainide unless prescriber orders inpatient crossover

• Reduction in frequency or severity of paroxysmal SVT or PAF episodes with fewer disabling palpitations
• Suppression of life-threatening sustained VT documented on monitor or symptom diary
• Stable hemodynamics without new conduction block beyond prescriber-accepted limits
• Trough flecainide level within 0.2–1 mcg/mL when levels are ordered—without PR ≥0.3 s or QRS ≥0.18 s unless prescriber accepts

Hold the dose and escalate immediately for proarrhythmia or high-grade conduction disease.

• New wide-complex tachycardia, sustained VT, or ventricular fibrillation on monitor—activate emergency response per protocol
• Second- or third-degree AV block, or bifascicular block without pacemaker backup—hold and notify prescriber
• PR interval ≥0.3 s or QRS ≥0.18 s, or symptomatic bradycardia with dizziness or syncope
• New or worsening heart failure symptoms—pulmonary edema, crackles, weight gain, or poor perfusion
• Paradoxical rapid ventricular response in atrial fibrillation or 1:1 conduction in atrial flutter

↔On a small screen, swipe or scroll sideways to see the full table.

No specific antidote is identified in the prescribing information for flecainide overdose. Overdoses up to 8000 mg have been survived, with peak plasma levels as high as 5.3 mcg/mL. Death has occurred with ingestion of as little as 1000 mg, often with concomitant drugs or alcohol.

Manifestations (labeling)

• Nausea, vomiting, convulsions, hypotension, bradycardia, syncope
• Extreme QRS and QT widening, PR prolongation, ventricular tachycardia, AV nodal block, asystole, bundle branch block, cardiac failure, cardiac arrest

Management (supportive)

• Remove unabsorbed drug from GI tract when appropriate
• Inotropic agents or cardiac stimulants such as dopamine, dobutamine, or isoproterenol per prescriber orders
• Mechanically assisted respiration and circulatory support (e.g., intra-aortic balloon pump) when indicated
• Transvenous pacing for conduction block
• Extended monitoring required because half-life is 12–27 hours; hemodialysis removes only ~1% of oral dose

• Flecainide vs other antiarrhythmics—verify generic name and strength; do not substitute amiodarone, sotalol, or propafenone without new orders
• 50 mg vs 100 mg vs 150 mg tablets—similar white round/scored appearances across strengths; scan bar code and read imprint
• Twice-daily vs three-times-daily scheduling—document exact times; missed doses followed by double dosing increases proarrhythmia risk
• Renal dose vs standard dose—CrCl ≤35 requires 100 mg daily or 50 mg BID start; flag mismatched MAR entries with pharmacy
• Amiodarone co-therapy—ensure flecainide was reduced 50% when amiodarone added; LASA errors include continuing full flecainide dose

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• 12-lead ECG for PR, QRS, and QT intervals at baseline, after each dose change, and at steady state
• Continuous telemetry during inpatient initiation for sustained VT or early outpatient titration when ordered
• Heart rate, blood pressure, and symptoms (dizziness, palpitations, dyspnea) each visit or shift during titration
• Trough flecainide plasma levels when prescribed—especially with renal/hepatic impairment, CHF, or amiodarone
• Renal function, electrolytes (potassium), and signs of heart failure
• Pacemaker capture thresholds when applicable

Document

• Indication, starting dose, and prescriber PR/QRS hold parameters
• Each dose change with paired ECG intervals and symptoms
• Plasma level results with date/time relative to dose
• Patient teaching on palpitation reporting and when to seek urgent care

• Take this heart rhythm medicine exactly every 12 hours (or as prescribed)—do not double up missed doses without calling your team
• Report dizziness, fainting, rapid pounding heartbeat, new shortness of breath, chest discomfort, or vision changes immediately
• It may take several days to reach full effect after a dose change—keep follow-up ECG and lab appointments
• Tell every clinician you take flecainide before new medicines are started—especially other heart rhythm drugs
• If breastfeeding, discuss with your prescriber—flecainide passes into breast milk

Do not administer and contact the prescriber/pharmacist when:

Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.

This NCLEX-style clinical judgment practice set for flecainide uses a tabbed inpatient case (MAR, labs, vitals, nursing notes), then rotates priority action, cue recognition, ECG trend interpretation, matrix urgency sorting, renal-dosing judgment, and documentation cloze—recognise proarrhythmia cues → analyse intervals and levels → prioritise hold/escalate → act → evaluate outcomes after dose or interaction changes.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.